Objectives: To describe NSAID utilization for musculoskeletal conditions in a large cohort of Italian elderly with cerebro/cardiovascular disease, a population in which NSAIDs should be generally avoided due to the prothrombotic potential. Methods: Administrative data from five Italian geographic areas were analyzed. Patients aged ≥ 65 with a cerebro/cardiovascular event recorded between 2008 and 2011 (cohort entry) were selected. Prescription NSAIDs reimbursed for musculoskeletal conditions and dispensed during 1 year follow-up were retrieved to describe (i) prevalence of use, (ii) average amount of defined daily doses of NSAIDs claimed by users per day of follow-up, and (iii) distribution of the received daily dose (RDD) among patients with ≥ 2 dispensings. Among new users, i.e., patients without NSAID dispensings during 2 years before cohort entry, the first dispensed NSAID molecule was observed. Results: Overall, 511,989 patients were selected. Across the five geographic areas, prevalence of use ranged from 48 to 21% and average consumption ranged between 30 and 67 DDD/1000 users/day. Around 10% of patients in the overall cohort had a RDD > 1. Nimesulide (9.6%) and diclofenac (7.5%) had the highest prevalence of use. The most consumed NSAIDs were nimesulide and coxibs with 10.6 and 7.5 DDD/1000 users/day, respectively. Among new users recruited in 2011, 30% had diclofenac or a coxibs as the first prescription. Conclusions: NSAID use was common in the study cohort, particularly in central-southern areas. In contrast with current recommendations, coxibs and diclofenac were among the most prescribed active principles, even in new users. Interventions to promote appropriateness of use are warranted.

NSAIDs utilization for musculoskeletal indications in elderly patients with cerebro/cardiovascular disease / Roberto G. , Bartolini C. , Rea F. , Onder G. , Vitale C. , Trifirò G. , Kirchmayer U. , Chinellato A. , Lucenteforte E. , Corrao G. , Mugelli A. , Lapi F. , Gini R. , Agabiti N. , Bartolini C. , Bernabei R. , Bettiol A. , Bonassi S. , Caputi A.P. , Cascini S. , Chinellato A. , Corrao G. , Davoli M. , Fini M. , Gini R. , Giorgianni F. , Kirchmayer U. , Lapi F. , Lombardi N. , Lucenteforte E. , Mugelli A. , Onder G. , Rea F. , Roberto G. , Sorge C. , Tari M. , Trifirò G. , Vannacci A. , Vetrano D.L. , Vitale C.. - In: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0031-6970. - ELETTRONICO. - (2018), pp. 1-7. [10.1007/s00228-018-2411-y]

NSAIDs utilization for musculoskeletal indications in elderly patients with cerebro/cardiovascular disease

Bartolini C.;REA, FEDERICO;Vitale C.;Chinellato A.;Lucenteforte E.;Mugelli A.;Bettiol A.;Chinellato A.;FINI STORCHI, MARCO;Lombardi N.;Lucenteforte E.;Mugelli A.;Rea F.;Vannacci A.;VITALE, CLAUDIA
2018

Abstract

Objectives: To describe NSAID utilization for musculoskeletal conditions in a large cohort of Italian elderly with cerebro/cardiovascular disease, a population in which NSAIDs should be generally avoided due to the prothrombotic potential. Methods: Administrative data from five Italian geographic areas were analyzed. Patients aged ≥ 65 with a cerebro/cardiovascular event recorded between 2008 and 2011 (cohort entry) were selected. Prescription NSAIDs reimbursed for musculoskeletal conditions and dispensed during 1 year follow-up were retrieved to describe (i) prevalence of use, (ii) average amount of defined daily doses of NSAIDs claimed by users per day of follow-up, and (iii) distribution of the received daily dose (RDD) among patients with ≥ 2 dispensings. Among new users, i.e., patients without NSAID dispensings during 2 years before cohort entry, the first dispensed NSAID molecule was observed. Results: Overall, 511,989 patients were selected. Across the five geographic areas, prevalence of use ranged from 48 to 21% and average consumption ranged between 30 and 67 DDD/1000 users/day. Around 10% of patients in the overall cohort had a RDD > 1. Nimesulide (9.6%) and diclofenac (7.5%) had the highest prevalence of use. The most consumed NSAIDs were nimesulide and coxibs with 10.6 and 7.5 DDD/1000 users/day, respectively. Among new users recruited in 2011, 30% had diclofenac or a coxibs as the first prescription. Conclusions: NSAID use was common in the study cohort, particularly in central-southern areas. In contrast with current recommendations, coxibs and diclofenac were among the most prescribed active principles, even in new users. Interventions to promote appropriateness of use are warranted.
2018
1
7
Roberto G. , Bartolini C. , Rea F. , Onder G. , Vitale C. , Trifirò G. , Kirchmayer U. , Chinellato A. , Lucenteforte E. , Corrao G. , Mugelli A. , Lapi F. , Gini R. , Agabiti N. , Bartolini C. , Bernabei R. , Bettiol A. , Bonassi S. , Caputi A.P. , Cascini S. , Chinellato A. , Corrao G. , Davoli M. , Fini M. , Gini R. , Giorgianni F. , Kirchmayer U. , Lapi F. , Lombardi N. , Lucenteforte E. , Mugelli A. , Onder G. , Rea F. , Roberto G. , Sorge C. , Tari M. , Trifirò G. , Vannacci A. , Vetrano D.L. , Vitale C.
File in questo prodotto:
File Dimensione Formato  
nsaids.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 600.09 kB
Formato Adobe PDF
600.09 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1117598
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact